Metronomic therapy for gynecologic cancers

Laparoscopy for Gynecologic Cancers

Gonadotropin-releasing hormone receptor-targeted gene therapy of gynecologic cancers.

The majority of ovarian, endometrial, and breast cancers express gonadotropin-releasing hormone (GnRH) receptors. Apart from reproductive organs (ovaries, fallopian tubes, and uterus) that are normally removed during surgical therapy of ovarian or endometrial cancer, pituitary gonadotrophs also express GnRH receptors. The signal transduction pathway in tumor cells is basically different from th...

Palliative Care in Gynecologic Cancers

Gynecologic cancers constitute a significant part of cancer load, especially in developing countries, and may be an important reason for mortality and morbidity for women in these countries. Procedures in diagnosis and treatment for gynecologic cancers might remain insufficient, and disorders related to symptoms may negatively influence the quality of life of women and their families. In this r...

Neoadjuvant Chemotherapy in Gynecologic Cancers

Neoadjuvant chemotherapy is introduced in many gynecologic cancers such as cervical and ovarian cancer. The aim of using neoadjuvant chemotherapy is to reduce the tumor size prior to the principle treatment, either radiation or surgery. The benefit of reducing tumor size can increase the operability and decrease the morbidity in many types of gynecologic cancers. Besides this, neoadjuvant chemo...

Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers

Immune checkpoint inhibitors have become an area of intense interest in oncology and are actively being studied in a variety of cancer types with a wide range of success. In vitro data suggest mechanisms by which radiation can activate the immune system, and ongoing studies are exploring the potential interaction of checkpoint inhibitors with radiotherapy in both preclinical and clinical settin...